497 results about "Treatment medication" patented technology

A diagnostic tool is disclosed for accurately and rapidly diagnosing the condition of an ailing organ. Although applicable to numerous organ and organ systems, this application particularly illustrates the concept of conjunctive marker utilization as it relates to diagnosing and distinguishing congestive heart failure. The invention particularly relates to the conjunctive utilization of cardiac Troponin I (cTn-I) and natriuretic peptide, e.g. ANP, pro-ANP, BNP, pro-BNP and CNP as a retrospective tool for diagnosing the underlying mechanism of heart failure and as a prospective analytical device for monitoring disease progression and efficacy of therapeutic agents.

The object of the present invention is to discover a combination of preventive or therapeutic drugs for glaucoma or ocular hypertension, which is useful as a preventive or therapeutic agent for glaucoma or ocular hypertension. By combining isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate with other preventive or therapeutic drug for glaucoma or ocular hypertension, their intraocular pressure lowering effects are complemented and/or enhanced each other. As for the administration form, these drugs may be administered concomitantly or may be administered as a combination drug.

The present invention provides a particulate composition wherein an oil component containing reduced coenzyme Q₁₀ is polydispersed forming a domain in a matrix containing a water-soluble excipient, which simultaneously shows high oxidative stability and high oral absorbability, a production method thereof, and a stabilizing method thereof. It also provides a food, food with nutrient function claims, food for specified health uses, dietary supplement, nutritional product, animal drug, drink, feed, pet food, cosmetic, pharmaceutical product, therapeutic drug, prophylactic drug and the like, which contain the composition.

The invention discloses application of serine, which is used as a biological marker and has +79.96685 mass shift at a 208 site of AKAP3 (A-kinase Anchor Protein 3), to preparation of a diagnostic reagent or a treatment medicine of severe oligoasthenospermia. According to the application disclosed by the invention, the severe oligoasthenospermi can be diagnosed through testing frequency of the +79.96685 mass shift occurring at the 208 site of the AKAP3, and new diagnosis and new treatment target spots are provided for the severe oligoasthenospermia.

The invention discloses 2-(1,6,7,8-tetrahydrogen-2H-indeno-[5,4-b] furan-8-group) acetonitrile (I), an optical isomer (II) thereof, a preparation method of the compound and application of the compound in preparing ramelteon which is a medicament for treating insomnia.

The invention provides a black phosphorus quantum dot composite material comprising a black phosphorus quantum dot, positive ions modified on the surface of the black phosphorus quantum dot and polyethylene glycol or polyethylene glycol derivatives. The positive ions comprise the metal positive ions or the ammonium ions. The positive ions are combined with the black phosphorus quantum dot through electrostatic force, and the pieces of polyethylene glycol or the polyethylene glycol derivatives are combined with the black phosphorus quantum dot through Van der Waals force. According to the black phosphorus quantum dot composite material, the positive ions are combined with the black phosphorus quantum dot through the electrostatic force, so that the oxidation resistance ability of the positive ions is improved greatly, and the pieces of polyethylene glycol or the polyethylene glycol derivatives are combined with the black phosphorus quantum dot through the Van der Waals force so that the black phosphorus quantum dot can be stably dispersed in water. The invention provides a preparation method of the black phosphorus quantum dot composite material in the second aspect. The method is simple and easy to operate. The black phosphorus quantum dot composite material can be used for preparing photoacoustic imaging drugs, or photothermal therapy drugs, or photodynamic therapy drugs or drug-loading targeted therapy drugs.

The invention discloses a medication decision-making support method based on drug knowledge map reasoning. According to the method, a patient interaction module, a medication decision-making support module and the like are arranged. The patient interaction module is used for acquiring pathophysiological information by means of voice interaction and check interaction and the like, thereby providingassistance for a doctor for prescription. The medication decision-making support module includes a treatment medication recommendation sub module and a safety medication examination sub module. The treatment medication recommendation sub module recommends one or more kinds of drugs for the doctor for prescription preliminarily based on information including patient diseases, taboos, and allergensand being obtained by the patient interaction module as well as drug information in a drug knowledge map; and the safety medication examination sub module is used for carrying out examination based on the medication safety situation of the patient by the patient. According to the method, drug recommendation is provided automatically by using the drug knowledge map and the pathophysiological information of the patient; and the doctor is assisted in make prescription and the drugs based on the prescription is processed by safety examination. Therefore, the basic information acquisition time ofthe patient by the doctor is saved; the doctor's diagnosis and treatment efficiency is improved obviously; and the safety of clinical medication is enhanced.

The invention provides a liquid medicine atomizing drainage device and method. A liquid medicine storing and atomizing cavity, a gas compression pump, a high-pressure airflow channel, a high-pressure airflow nozzle, a liquid medicine absorbing pipe and a spacer; an atomizing opening is formed in the upper end of the liquid medicine storing and atomizing cavity and is connected with a corrugated pipe through a first one-way valve, and the corrugated pipe is connected with an atomizing cover; the atomizing cover is connected with an expiration exhaust opening through a second one-way valve, a first pressure sensor is arranged on the inner side wall of the atomizing cover, a second pressure sensor is arranged in the liquid medicine storing and atomizing cavity, a controller and a power module are arranged in the shell, the controller is connected with the gas compression pump through control switch signals, and the controller is connected with the first pressure sensor, the first one-way valve and the second pressure sensor in a signal mode. Along with breath of a patient, medicine mist is automatically controlled to be exhausted effectively, the medicine can be fully absorbed and used by the patient, and waste of the treatment medicine is avoided.

A novel hemopoietin receptor gene (NR12) was successfully isolated by extracting motifs conserved among the amino acid sequences of known hemopoietin receptors and by using the predicted sequence. The NR12 gene encodes two forms of proteins, a transmembrane type and a soluble type. The expression of the NR12 gene was detected in tissues containing hematopoietic cells. NR12 is a novel hemopoietin receptor molecule involved in the regulation of immune system and hematopoiesis in vivo. Thus, NR12 is useful in the search for novel hematopoietic factors that functionally bind to the NR12 receptor, and in the development of therapeutic drugs for diseases associated with immunity or hematopoiesis.

The invention belongs to the field of drug detection, and particularly relates to a method and a kit for detecting five psychotropic drugs and main metabolites thereof in blood. The five psychotropicdrugs and the main metabolites thereof comprise: olanzapine and demethyl olanzapine, risperidone and 9-hydroxy risperidone, aripiprazole and dehydrogenated aripiprazole, Escitalopram and demethyl citalopram, sertraline and N-demethyl sertraline. Accoridng to the method provided by the invention, a pair of quantitative ion pairs is respectively selected for each detection substance, a relative retention time thereof is used as a qualitative basis, and a standard curve is made by using a standard product for quantification; furthermore, the accuracy and effectiveness of the method are evaluatedfrom quality control of three low, middle and high levels, thereby avoiding distortion of the detection result; and meanwhile, an internal standard working solution is applied to correction, so that matrix effects can be avoided, and accurate quantification is realized. The method provided by the invention has the advantages of simple and rapid operation, high flux and low cost, and can be appliedto the therapeutic drug monitoring of the psychotropic drugs in the clinical work of the psychiatry department.

The present invention relates generally to the field of identification and determination of bioactive amino acid sequences. In particular, the present invention provides method(s) for determining the influence of variation in host genes on selection of microorganisms with particular amino acid variants for the purpose of therapeutic drug or vaccine design or individualisation of such treatment. The invention also provides methods for identifying HLA allele-specific microorganism sequence polymorphisms that result from HLA restriction of antigen-specific cellular immune responses. It also provides diagnostic and therapeutic methodologies that may be used to measure or treat infection by a microorganism or to prevent infection by the microorganism.

The invention relates to a hyaluronic acid-nano silver-based dressing and a preparation method thereof. The hyaluronic acid-nano silver-based dressing comprises therapeutic drugs, nano silver, hyaluronic acid and degradable synthetic high polymers. The method mainly utilizes an electrostatic spinning technique to proportionally mix a solution containing nano silver and hyaluronic acid with a solution containing therapeutic drugs and synthetic high polymers and process the nano fiber nonwoven fabric. The obtained hyaluronic acid-nano silver-based dressing has the characteristics of favorable uniformity, high porosity, favorable air permeability and favorable biocompatibility. In the hyaluronic acid-nano silver-based dressing preparation process, water is used as the solvent, so no organic solvent residue exists. The method has the advantage of simple technique and low cost. The prepared hyaluronic acid-nano silver-based dressing has wide application range, and can be used for various surgical cuts, burn and scald surfaces, various traumatic wound surfaces, peripheral ulcer surfaces and various non-healing chronic ulcer wound surfaces.

A current system allows data-driven hypothesis generation to identify therapeutic candidates for a disease phenotype treatment by identifying drugs and clinical indications associated with lower occurrences of disease-associated phenotype(s) by a drug/drug class. A current system may include a pharmaceutical hierarchical ontology; a phenotype hierarchical ontology; a record database comprising clinical event records; a database mining engine; and a mapping engine. The database mining engine may iteratively progress through a portion of the pharmacological hierarchical ontology and phenotype hierarchical ontology to iteratively select pairs of cohort entries from each ontology; and for each pair of cohort entries, query the clinical record database for matching records. The mapping engine may map each pair of cohort entries into a matrix comprising a drug-event cell for each pair and apply a value thereto representing the number of database records matching items returned by the database mining engine for the corresponding cohort entries.

The present invention is directed to systems and methods for diagnosing tissue abnormality or diseases, determining effective drug dosages, and monitoring therapeutic drug treatments. The methods and systems described utilize tissue imaging in situ and computer modeling.

The invention discloses traditional Chinese medicine composition for treating oral ulcer, belongs to the field of traditional Chinese medicine, and aims at overcoming the defect that chemotherapeutic drugs for treating the oral ulcer are high in hepatotoxicity at present. The traditional Chinese medicine composition for preventing or treating the oral ulcer comprises the raw materials in parts by weight as follows: 12-16 parts of scutellaria baicalensis, 5-8 parts of honeysuckle, 8-12 parts of pericarpium granati, 8-12 parts of calyx seu fructus physalis, 8-12 parts of radix asparagi, 18-22 parts of dandelion, 18-22 parts of cicada slough, 8-12 parts of lotus leaves, 5-8 parts of radix paeoniae alba, 5-8 parts of mint, 12-16 parts of underleaf pearl, 5-8 parts of fructus arctii, 8-12 parts of goldthread, 8-12 parts of liquorice, 8-12 parts of pseudo-ginseng, 18-22 parts of hawthorn, 8-12 parts of roots of Chinese thorowax, 5-8 parts of roots of red-rooted salvia, 5-8 parts of Chinese gall, 8-12 parts of rhizome of oriental water plantain and 28-32 parts of rhizoma atractylodis. The traditional Chinese medicine composition has a good treatment effect in treating the oral ulcer and obvious clinical promotion values.

The invention discloses a Tribonema sp. PD2 strain with a preservation number of CGMCC No.10488, and application thereof in the production of biodiesel, palmitoleic acid, feed, food, skin care products, and therapeutic drugs for cardiovascular and cerebrovascular diseases, and in the carbon dioxide emission reduction, and waste gas treatment and/or wastewater treatment. The Tribonema sp. PD2 strain has the advantages of fast growth, high biomass and easiness in harvesting, and is suitable for industrial application. The oil content of the Tribonema sp. PD2 strain is as much as 60% or more of the dry biomass, wherein the content of C16-C18 is as much as 85% of the total fatty acids, the content of the palmitoleic acid (C16:1omega7) is no less than 45% of the total fatty acids, and the content of the total unsaturated fatty acids is as much as 65% of the total fatty acids. Therefore the Tribonema sp. PD2 strain is especially suitable for the production of biodiesel and the development of health care products and foods.

The invention discloses a monoclonal antibody MERS-4, as well as a coding gene and an application thereof. The antibody provided by the invention is named monoclonal antibody MERS-4, comprises a chain A and a chain B, wherein the chain A is (a) protein consisting of an amino acid sequence as shown in a sequence 1 or (b) protein which is derived from the sequence 1 by substituting and/or deleting and/or adding one or more amino acid residues on the sequence 1 and has the same function; and the chain B is (c) protein comprising an amino acid sequence as shown in a sequence 3 or (d) which is derived from the sequence 3 by substituting and/or deleting and/or adding one or more amino acid residues on the sequence 3 and has the same function. The monoclonal antibody can be used for effectively inhibiting MERS-CoV invasion cells, can be used as medicines for preventing or treating MERS-CoV, and has an important theoretical guiding value and a wide application prospect for prevention and treatment of MERS-CoV.